Pascal and Francis Bibliographic Databases

Help

Search results

Your search

au.\*:("WHITE, Kirsten")

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 27

  • Page / 2
Export

Selection :

  • and

Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participantsPALELLA, Frank J; FISHER, Martin; WHITE, Kirsten et al.AIDS (London). 2014, Vol 28, Num 3, pp 335-344, issn 0269-9370, 10 p.Article

HIV-2 Antiviral Potency and Selection of Drug Resistance Mutations by the Integrase Strand Transfer Inhibitor Elvitegravir and NRTIs Emtricitabine and Tenofovir In VitroANDREATTA, Kristen; MILLER, Michael D; WHITE, Kirsten L et al.Journal of acquired immune deficiency syndromes (1999). 2013, Vol 62, Num 4, pp 367-374, issn 1525-4135, 8 p.Article

Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trialPOZNIAK, Anton; MARKOWITZ, Martin; GARNER, Will et al.Lancet. Infectious diseases (print). 2014, Vol 14, Num 7, pp 590-599, issn 1473-3099, 10 p.Article

Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adultsCOHEN, Calvin; WOHL, David; WHITE, Kirsten et al.AIDS (London). 2014, Vol 28, Num 7, pp 989-997, issn 0269-9370, 9 p.Article

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trialDEJESUS, Edwin; ROCKSTROH, Jürgen K; CHENG, Andrew K et al.Lancet (British edition). 2012, Vol 379, Num 9835, pp 2429-2438, issn 0140-6736, 10 p.Article

Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trialARRIBAS, Jose R; PIALOUX, Gilles; GATHE, Joseph et al.Lancet. Infectious diseases (print). 2014, Vol 14, Num 7, pp 581-589, issn 1473-3099, 9 p.Article

A Randomized Study of Tenofovir Disoproxil Fumarate in Treatment-experienced HIV-1 Infected AdolescentsDELLA NEGRA, Marinella; PROHMANN DE CARVALHO, Aroldo; CHUCK, Steven L et al.The Pediatric infectious disease journal. 2012, Vol 31, Num 5, pp 469-473, issn 0891-3668, 5 p.Article

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeksSAX, Paul E; DEJESUS, Edwin; WHITE, Kirsten et al.Lancet (British edition). 2012, Vol 379, Num 9835, pp 2439-2448, issn 0140-6736, 10 p.Article

Dead-end complexes contribute to the synergistic inhibition of HIV-1 RT by the combination of rilpivirine, emtricitabine, and tenofovirKULKARNI, Rima; FENG, Joy Y; MILLER, Michael D et al.Antiviral research. 2014, Vol 101, pp 131-135, issn 0166-3542, 5 p.Article

The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65R+M184VLY, John K; MARGOT, Nicolas A; MACARTHUR, Holly L et al.Antiviral chemistry & chemotherapy. 2007, Vol 18, Num 6, pp 307-316, issn 0956-3202, 10 p.Article

APC I1307K and the risk of prostate cancerPOYNTER, Jenny N; COONEY, Kathleen A; BONNER, Joseph D et al.Cancer epidemiology, biomarkers & prevention. 2006, Vol 15, Num 3, pp 468-473, issn 1055-9965, 6 p.Article

Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacityWHITE, Kirsten L; MARGOT, Nicolas A; WRIN, Terri et al.Antimicrobial agents and chemotherapy. 2002, Vol 46, Num 11, pp 3437-3446, issn 0066-4804, 10 p.Article

Inhibition of 2',5'-Oligoadenylate Synthetase Expression and Function by the Human Cytomegalovirus ORF94 Gene ProductTAN, Joanne C. G; AVDIC, Selmir; CAO, John Z et al.Journal of virology. 2011, Vol 85, Num 11, pp 5696-5700, issn 0022-538X, 5 p.Article

Mechanism of Resistance to GS-9148 Conferred by the Q151L Mutation in HIV-1 Reverse TranscriptaseSCARTH, Brian J; WHITE, Kirsten L; CHEN, James M et al.Antimicrobial agents and chemotherapy. 2011, Vol 55, Num 6, pp 2662-2669, issn 0066-4804, 8 p.Article

Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovirMARCHAND, Bruno; WHITE, Kirsten L; LY, John K et al.Antimicrobial agents and chemotherapy. 2007, Vol 51, Num 8, pp 2911-2919, issn 0066-4804, 9 p.Article

The HIV-1 Reverse Transcriptase MI841 Mutation Enhances the E138K-Associated Resistance to Rilpivirine and Decreases Viral FitnessKULKARNI, Rima; BABAOGLU, Kerim; LANSDON, Eric B et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 59, Num 1, pp 47-54, issn 1525-4135, 8 p.Article

The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutationsWHITE, Kirsten L; CHEN, James M; FENG, Joy Y et al.Antiviral therapy (London). 2006, Vol 11, Num 2, pp 155-163, issn 1359-6535, 9 p.Article

The A62V and S68G Mutations in HIV-1 Reverse Transcriptase Partially Restore the Replication Defect Associated With the K65R MutationSVAROVSKAIA, Evguenia S; FENG, Joy Y; MILLER, Michael D et al.Journal of acquired immune deficiency syndromes (1999). 2008, Vol 48, Num 4, pp 428-436, issn 1525-4135, 9 p.Article

A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RTWHITE, Kirsten L; MARGOT, Nicolas A; LY, John K et al.AIDS (London). 2005, Vol 19, Num 16, pp 1751-1760, issn 0269-9370, 10 p.Article

Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patientsWATERS, Joshua M; O'NEAL, Wesley; WHITE, Kirsten L et al.Antiviral therapy (London). 2009, Vol 14, Num 2, pp 231-239, issn 1359-6535, 9 p.Article

Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutationsWHITE, Kirsten L; CHEN, James M; MARGOT, Nicolas A et al.Antimicrobial agents and chemotherapy. 2004, Vol 48, Num 3, pp 992-1003, issn 0066-4804, 12 p.Article

In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4MARGOT, Nicolas A; HLUHANICH, Rebecca M; JONES, Gregg S et al.Antiviral research. 2012, Vol 93, Num 2, pp 288-296, issn 0166-3542, 9 p.Article

Truncating BRCA1 mutations are uncommon in a cohort of hereditary prostate cancer families with evidence of linkage to 17q markersZUHLKE, Kimberly A; MADEOY, Jennifer J; BEEBE-DIMMER, Jennifer et al.Clinical cancer research. 2004, Vol 10, Num 18, pp 5975-5980, issn 1078-0432, 6 p.Article

Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication FitnessABRAM, Michael E; HLUHANICH, Rebecca M; SVAROVSKAIA, Evguenia S et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 6, pp 2654-2663, issn 0066-4804, 10 p.Article

Fine-mapping the putative chromosome 17q21-22 prostate cancer susceptibility gene to a 10 cM region based on linkage analysisLANGE, Ethan M; ROBBINS, Christiane M; CARPTEN, John D et al.Human genetics. 2007, Vol 121, Num 1, pp 49-55, issn 0340-6717, 7 p.Article

  • Page / 2